Core Insights - Perimeter Medical Imaging AI, Inc. has entered into an agreement with Intermountain Health to deploy its advanced S-Series OCT imaging technology in operating rooms across two hospitals in Utah, enhancing surgical decision-making and patient outcomes [1][3] Company Overview - Perimeter Medical Imaging AI is a commercial-stage medical technology company focused on transforming cancer surgery through ultra-high-resolution, real-time imaging tools [5] - The company's S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level and has received FDA clearance [5][6] Partnership Details - The agreement allows any hospital within the Intermountain Health system, which includes 34 hospitals and approximately 400 clinics across multiple states, to acquire Perimeter's imaging technology [2][4] - This collaboration builds on a previous Development Support Agreement aimed at evaluating the potential value of Perimeter's OCT technology and supporting the development of its AI algorithms [3] Technology Impact - The S-Series OCT technology is designed to assist surgeons by providing real-time visualization of tissue margins, which supports more informed surgical decisions [2][3] - The partnership is expected to extend Perimeter's technology into new states, enhancing the capabilities of surgeons and improving patient care [3]

Franklin Lakes, New Jersey-based Becton, Dickinson and Company (BDX) is a medical technology company with a market cap of $57.8 billion. The company is ready to announce its fiscal Q1 earnings for 2026 in the near future. Before this event, analysts expect this healthcare company to report a profit of $2.82 per share, down 17.8% from $3.43 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters. In Q4, its EPS of $3.96 exceeded the co ...

Core Insights - Enovis Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST [1] - The company focuses on developing clinically differentiated medical technology solutions to enhance patient outcomes and restore motion [2] Company Overview - Enovis is a global innovator in medical technology, dedicated to improving lives through advanced healthcare solutions [2] - The company collaborates with leading health professionals to provide smarter, personalized, and effective care while enhancing operational efficiency for surgeons and clinicians [2] - Enovis solutions positively impact the well-being of millions of patients globally [2] Information Availability - Enovis regularly announces material information through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [3] - The company encourages stakeholders to review the information shared on its Investor Relations website for potentially material updates [3]

Core Viewpoint - InMode Ltd. is set to release its financial results for Q4 and the full year of 2025 on February 10, 2026, with preliminary revenue estimates indicating strong performance [1][2][7]. Financial Results - Preliminary revenue for Q4 2025 is expected to be between $103.6 million and $103.8 million, while the full year revenue is projected to be in the range of $370.2 million to $370.4 million [7]. - The non-GAAP gross margin for the full year of 2025 is anticipated to be between 78% and 79% [7]. - Revenue for the full year of 2026 is projected to be between $365 million and $375 million [7]. Conference Call Details - A conference call to discuss the financial results will take place on February 10, 2026, at 8:30 a.m. Eastern Time, featuring key executives including the CEO, CFO, and CTO [3][4]. - Participants are encouraged to pre-register for the call to receive a unique dial-in number for immediate access [4][5]. Company Overview - InMode is recognized as a leading global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology for various medical applications [8].

With a market cap of $16.7 billion, Hologic, Inc. (HOLX) is a global medical technology company focused on improving women’s health through the development, manufacture, and supply of diagnostic products, medical imaging systems, and surgical solutions. The company operates across Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments to support early detection and treatment worldwide. The Marlborough, Massachusetts-based company is set to unveil its fiscal Q1 2026 results soon. Ahead of ...

BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026. The call can be accessed via teleconference at: Q3 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

Core Insights - Sanara MedTech's BIASURGE Advanced Surgical Solution has been awarded an Innovative Technology contract by Vizient, indicating its potential to improve healthcare outcomes and reduce costs in the surgical market [1][3][4] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare expenditures in the surgical market [7][8] - The company offers a range of surgical products, including BIASURGE, CellerateRX Surgical Activated Collagen Powder, and FORTIFY TRG Tissue Repair Graft, among others [8] Product Details - BIASURGE is a no-rinse irrigation solution designed for efficient surgical cleansing, featuring an antimicrobial preservative that provides broad-spectrum effectiveness against pathogenic microorganisms [5][6] - The product is optimized for pH, viscosity, and osmolality to ensure maximum performance while maintaining safety and effectiveness [5] - BIASURGE enhances surgical precision and visibility by maintaining a cleaner operative field, supporting infection-control strategies [6] Contract Significance - The Innovative Technology contract allows Vizient's extensive network of healthcare facilities to access BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026 [3][4] - The contract was awarded based on recommendations from hospital experts, highlighting BIASURGE's unique benefits over existing market products [3][4]

Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for Medicare & Medicaid Services’ (“CMS”) Local Coverage Determinations (“LCD”) for skin substitute grafts/cellular and tissue-based produc ...

Core Viewpoint - Ventripoint Diagnostics Ltd. is responding to significant investor interest by doubling its non-brokered private placement from $500,000 to $1,000,000, pending approval from the TSX Venture Exchange [1]. Group 1: Offering Details - Each unit in the offering will consist of one common share and one common share purchase warrant [2]. - Each warrant allows the holder to purchase one common share at a price of $0.13 for a period of 24 months from the closing of the offering, with the potential for an accelerated expiry if the common shares trade at $0.26 or above for 10 consecutive days [3]. - The corporation may pay a cash finder's fee and issue finder's warrants of up to 8% of the gross proceeds, with each finder's warrant also exercisable into one common share at the same price of CDN$0.13 for 24 months [4]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized to support critical commercialization activities, manufacturing scale-up, continued regulatory submissions, and operational requirements [5]. Group 3: Company Overview - Ventripoint has established itself as a leader in AI-powered echocardiography, with its VMS+ products providing accurate volumetric cardiac measurements comparable to MRI, developed over a decade [9]. - The technology is designed to be an affordable alternative, enhancing cardiologists' confidence in patient management and is compatible with all ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [9].

Core Insights - A national survey indicates a significant shift in U.S. patients' expectations towards greater control over diagnostic testing, moving away from traditional evidence-based medicine [1][8] Patient Expectations - 93% of patients expect their doctor to order a lab test upon request, with 37% having requested tests based on personal research and 17% influenced by social media [2][12][13] - High interest in predictive health insights is noted, with 89% of respondents expressing interest in lab tests that can predict health risks [3] Testing Behavior - 27% of patients pursued blood testing independently of a doctor's recommendation, driven by curiosity [3][12] - Nearly half (49%) of those who engaged in self-prescribed testing do not share results with healthcare providers, indicating a trend towards privacy in health information [5] Trust in Healthcare Providers - While 95% of patients trust their providers to order appropriate tests, only 87% trust their guidance against requested tests, highlighting a changing dynamic in patient-provider relationships [4] Financial Aspects - A significant portion of patients face financial barriers, with 52% of those with unpaid medical bills indicating that their debt includes unpaid lab testing fees [6] - Patients are more likely to delay imaging (22%) than bloodwork (5%) when cost is a concern [7] Impact of Reimbursement Cuts - Upcoming payment cuts of up to 15% for around 800 laboratory tests threaten to widen the gap between patient expectations and what testing providers can deliver [8] - The RESULTS Act is gaining support as a potential solution to stabilize payments for laboratory tests and maintain access to quality services [8] Industry Perspective - Siemens Healthineers emphasizes the need for sustained investment in laboratory services to advance personalized care and fulfill the demand for predictive health insights [9]